Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Haemonetics Expects 2024 Revenue Growth Of 5%-8% On Reported Basis And 0%-3% On Organic Basis

Author: Benzinga Newsdesk | May 09, 2024 06:59am

Posted In: HAE